KID-CLOT: National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT03887143
Collaborator
(none)
70
1
25.8
2.7

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate recanalization treatments use, safety and efficacy at the acute phase of arterial ischemic stroke in pediatric patients

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Arterial ischemic stroke outcomes benefited from the implementation of recanalization treatments (IV thrombolysis, endovascular treatments) and adapted management pathways in adult patients. Nevertheless randomized trials did not enroll patients under the age of 18 years old and data concerning these treatments in children are scarce. As it is much less frequent than in adults, recognition of stroke is often delayed in children. Consequently, acute phase trials are difficult to set up and perform. The phase I multicentric international prospective trial TIPS (Thrombolysis in Pediatric Stroke) was prematurely stopped because of poor enrollment. Published retrospective regional (Paris-Ile-de-France region, France) and national (Switzerland) studies addressed the feasibility of such treatments but, because of small samples (less than 20 patients in each study), efficiency and prognostic factors could not be addressed.

    Exhaustive retrospective studies in a definite geographic area but with a sufficient number of patients in a limited inclusion period would provide these crucial data and address these questions with good relevance and limited bias.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    70 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke (Intra-venous Thrombolysis and/or Endovascular Treatment: Thrombectomy, Intra-arterial Thrombolysis)
    Actual Study Start Date :
    Apr 4, 2019
    Actual Primary Completion Date :
    May 29, 2021
    Actual Study Completion Date :
    May 29, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Arterial ischemic stroke in patients less than 18 years old

    Patients < 18 years old Suspected or confirmed cerebral infarction With recanalization treatment in the acute phase: intra-venous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy Patients treated between January 2015, 1st and May 2018, 31st

    Outcome Measures

    Primary Outcome Measures

    1. Acute management of stroke: [1 day]

      Median time from symptom onset to Imaging (minutes)

    2. Acute management of stroke: [1 day]

      Median time from symptom onset to beginning of recanalization treatment (minutes)

    3. Acute management of stroke: [1 day]

      Median door-to-needle delay (minutes)

    Secondary Outcome Measures

    1. Treatment-emergent adverse events: [7 days]

      Intracranial hemorrhage (yes/no)

    2. Treatment-emergent adverse events: [7 days]

      clinically symptomatic (yes/no)

    3. Treatment-emergent adverse events: [7 days]

      Peripheral hemorrhage (yes/no)

    4. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      age of onset (year, months)

    5. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      Mechanism of stroke (CASCADE classification)

    6. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      stroke location (name of artery territory)

    7. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      time from symptom onset to beginning of recanalization treatment (minutes)

    8. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      initial imagine ASPECT Alberta Stroke Program Early CT Score. score (units on an scale). The ASPECTS score is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke. I has also been adapted to be used with MR scans. All scale ranges : Segmental assessment of the MCA vascular territory is made and 1 point is deducted from the initial score of 10 for every region involved (caudate, putamen, internal capsule, nsular cortex, M1(anterior MCA cortex=frontal operculum), M2(MCA cortex lateral to insular ribbon=anterior temporal lobe), M3(posterior MCA cortex=posterior temporal lobe, M4(anterior MCA territory immediately superior to M1), M5(lateral MCA territory immediately superior to M2), M6(posterior MCA territory immediately superior to M3) For each scale, values better or worse : In adults, an ASPECTS score less than or equal to 7 predicts a worse functional outcome at 3 months as well as symptomatic hemorrhage

    9. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      Association with :Modified Rankin Scale - mRS (Units on a scale)The mRS is a 6-point quantitative measure of functional independence. All scale ranges: 0=No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance disability; requiring some help, but able to walk without assistance Moderate Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead For each scales range, values better or worse : In the literature, good outcome is usually considered for patients with mRS [0-2]. Very good outcome is considered for patients with mRS [0-1]. We will use the same thresholds

    10. factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis [12 months]

      Association with : - The Pediatric Stroke Outcome Measure - PSOM (Units on a scale) =scale has been designed and published to quantify functional consequences of stroke in children. The PSOM is a detailed neurological examination, with outcome scored in terms of degree of impairment in each of language, cognition, and sensorimotor. We wil use the PSOM-SNE version (PSOM-Short Neuro Exam version). All scale ranges (0-0,5-1 or 2): - Sensorimotor deficit, Language Deficit - Production, Language Deficit - Comprehension, Cognitive or Behavioural Deficit. Total score on 10 For each scale range, values better or worse: Total impairment scores (out of a maximum of 10) will be considered as previously published, i.e. total score 0 or 0.5 representing good outcome, and poor outcome ≥1. All subscales ranges (Normal, Anormal, Not Done): Level of consciousness, Behaviour, mental status, Language, Cranial nerves, Motor testing, Tendon reflexes, Fine motor coordination, Sensory, Gate

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients under 18 years old

    • Suspected or confirmed cerebral infarction

    • With recanalization treatment in the acute phase : intravenous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy

    • Patients treated between the January 2015, 1st and the May 2018, 31st

    • Collection of non-opposition from legal representatives

    Exclusion Criteria:
    • Refusal of the patient's legal representative to participate in the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Necker- Enfants Malades Hospital Paris France 75015

    Sponsors and Collaborators

    • Assistance Publique - Hôpitaux de Paris

    Investigators

    • Principal Investigator: Manoelle Kossorotoff, MD, PhD, Assistance Publique - Hôpitaux de Paris

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Assistance Publique - Hôpitaux de Paris
    ClinicalTrials.gov Identifier:
    NCT03887143
    Other Study ID Numbers:
    • NI18025HLJ
    First Posted:
    Mar 22, 2019
    Last Update Posted:
    Nov 22, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Assistance Publique - Hôpitaux de Paris
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 22, 2021